Matthew has extensive experience relating to the pharmaceutical industry, having started his career in medicinal chemistry at GSK where he delivered small molecule development candidates for neurological indications, such as Alzheimer's Disease and neuropathic and inflammatory pain.
Matthew specializes in obtaining and defending rights relating to pharmaceutical subject matter including new chemical entities, crystal forms, synthetic processes, intermediates, formulations, combination products and medical uses. In addition to European patent drafting and prosecution, Matthew also manages the prosecution of patent portfolios worldwide, and also has experience of obtaining Supplementary Protection Certificates (SPCs) in many European countries.
He regularly provides advice to clients on EPO opposition and appeal strategy and has successfully defended and attacked patent rights covering various commercial products via the central opposition procedure at the EPO. Matthew also regularly assist his clients with due diligence activities associated with in-licencing, such as freedom-to-operate opinions.
Besides pharmaceuticals, Matthew regularly assists his clients obtain and defend patent rights in relation to agrochemicals, catalysis, polymers, cleantech and food science.
Chemistry and Pharmacology
Certificate in Intellectual Property Law
Patent Attorney Litigator
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.